Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

With the advent of high active antiretroviral therapy there was a significant improvement on HIV subjects survival. Thus, bone changes related to HIV became an important aspect of these individuals. HIV affects bone remodeling causing bone fragility. In addition, antiretroviral therapy may also negatively affect bone metabolism. Several studies describe an increased incidence of fractures in these patients when compared with controls without the disease. The European Society of AIDS (EACS), and other societies, have included guidance on management of osteoporosis in HIV-infected patients emphasizing the identification of patients with low bone mass. Supplementation of calcium and vitamin D and the use of alendronate in these individuals should be recommended on a case base.

Type

Journal article

Journal

Arq Bras Endocrinol Metabol

Publication Date

07/2014

Volume

58

Pages

478 - 483

Keywords

Aging, Anti-Retroviral Agents, Bone Density, Bone and Bones, Female, Fractures, Bone, HIV Infections, Humans, Male, Osteoporosis, Osteoporotic Fractures, Risk Factors